The blockade of immune checkpoints in cancer immunotherapy
D. Pardoll
|
13 |
2012 |
13
2012
|
MicroRNA signatures in human cancers
G. Calin,
C. Croce
|
12 |
2006 |
12
2006
|
Oncomirs — microRNAs with a role in cancer
A. Esquela-Kerscher,
F. Slack
|
12 |
2006 |
12
2006
|
Epithelial–mesenchymal transitions in tumour progression
J. Thiery
|
12 |
2002 |
12
2002
|
Targeting HIF-1 for cancer therapy
G. Semenza
|
12 |
2003 |
12
2003
|
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
I. Vivanco,
C. Sawyers
|
12 |
2002 |
12
2002
|
New functions for the matrix metalloproteinases in cancer progression
M. Egeblad,
Z. Werb
|
12 |
2002 |
12
2002
|
Multidrug resistance in cancer: role of ATP–dependent transporters
M. Gottesman,
T. Fojo,
S. Bates
|
12 |
2002 |
12
2002
|
Hypoxia — a key regulatory factor in tumour growth
A. Harris
|
12 |
2002 |
12
2002
|
5-Fluorouracil: mechanisms of action and clinical strategies
D. Longley,
D. Harkin,
P. Johnston
|
12 |
2003 |
12
2003
|
Photodynamic therapy for cancer
D. Dolmans,
D. Fukumura,
R. Jain
|
12 |
2003 |
12
2003
|
Why do cancers have high aerobic glycolysis?
R. Gatenby,
R. Gillies
|
12 |
2004 |
12
2004
|
The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited
I. Fidler
|
12 |
2003 |
12
2003
|
Fibroblasts in cancer
R. Kalluri,
M. Zeisberg
|
12 |
2006 |
12
2006
|
Regulation of cancer cell metabolism
R. Cairns,
I. Harris,
T. Mak
|
12 |
2011 |
12
2011
|
Cancer nanotechnology: opportunities and challenges
M. Ferrari
|
12 |
2005 |
12
2005
|
Cancer nanomedicine: progress, challenges and opportunities
Jinjun Shi,
P. Kantoff,
R. Wooster,
O. Farokhzad
|
12 |
2016 |
12
2016
|
The immune contexture in human tumours: impact on clinical outcome
W. Fridman,
F. Pagès,
C. Sautès-Fridman,
J. Galon
|
12 |
2012 |
12
2012
|
Microtubules as a target for anticancer drugs
M. Jordan,
L. Wilson
|
12 |
2004 |
12
2004
|
